{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:50:09Z","timestamp":1775091009589,"version":"3.50.1"},"reference-count":97,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CMAR"],"DOI":"10.2147\/cmar.s328058","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T09:50:08Z","timestamp":1636537808000},"page":"8457-8471","source":"Crossref","is-referenced-by-count":34,"title":["The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?"],"prefix":"10.2147","volume":"Volume 13","author":[{"given":"Michael Patrick","family":"Lux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriana","family":"Ciani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William CN","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ferris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,11]]},"reference":[{"key":"ref1","unstructured":"NICE Decision Support Unit. NICE DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching; 2014. Available from: http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/TSD16_Treatment_Switching.pdf. Accessed March 13, 2020."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"j4528","DOI":"10.1136\/bmj.j4528","volume":"359","author":"Prasad","year":"2017","journal-title":"BMJ"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1562861","DOI":"10.1080\/20016689.2018.1562861","volume":"7","author":"Sola-Morales","year":"2019","journal-title":"J Mark Access Health Policy"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jval.2019.10.010","volume":"23","author":"Pinto","year":"2020","journal-title":"Value Health"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.healthpol.2014.08.004","volume":"118","author":"Ruof","year":"2014","journal-title":"Health Policy (New York)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"6517","DOI":"10.1200\/JCO.2018.36.15_suppl.6517","volume":"36","author":"Chen","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref7","first-page":"1","volume":"10","author":"Dilla","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"ref8","unstructured":"Looking to the future: oncology endpoints (summary report of a joint workshop held on of 3 July 2017 by the Academy of Medical Sciences and the Association of the British Pharmaceutical Industry); 2017. Available from: https:\/\/acmedsci.ac.uk\/file-download\/41135280. Accessed February 8, 2021."},{"key":"ref9","unstructured":"Vintura. Every day counts: improving time to patient access to innovative oncology therapies in Europe; 2020. Available from: https:\/\/www.efpia.eu\/media\/578013\/every-day-counts.pdf. Accessed January 12, 2021."},{"key":"ref10","unstructured":"EFPIA. The root cause of unavailability and delay to innovative medicines: reducing the time before patients have access to innovative medicines; 2020. Available from: https:\/\/www.efpia.eu\/media\/554527\/root-causes-unvailability-delay-cra-final-300620.pdf. Accessed April 20, 2021."},{"key":"ref11","unstructured":"OECD. Addressing challenges in access to oncology medicines \u2013 analytical report; 2020. Available from: https:\/\/www.oecd.org\/health\/health-systems\/Addressing-Challenges-in-Access-to-Oncology-Medicines-Analytical-Report.pdf. Accessed April 21, 2021."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.hlpt.2015.10.005","volume":"5","author":"Ciani","year":"2016","journal-title":"Health Policy Technol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2020.01.011","volume":"129","author":"Hofmarcher","year":"2020","journal-title":"Eur J Cancer"},{"key":"ref14","unstructured":"Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics - guidance for industry; 2018. Available from: https:\/\/www.fda.gov\/media\/71195\/download. Accessed January 23, 2020."},{"key":"ref15","first-page":"91","volume":"7","author":"Dudley","year":"2016","journal-title":"J Adv Pract Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s40425-019-0594-0","volume":"7","author":"Kaufman","year":"2019","journal-title":"J Immuno Ther Cancer"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","volume":"4","author":"Dafni","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1017\/S0266462314000300","volume":"30","author":"Ciani","year":"2014","journal-title":"Int J Technol Assess Health Care"},{"key":"ref19","unstructured":"European Medicines Agency. Guideline on the evaluation of anticancer medicinal products in man; 2017. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-anticancer-medicinal-products-man-revision-5_en.pdf. Accessed March 13, 2020."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.jval.2019.03.007","volume":"22","author":"Kordecka","year":"2019","journal-title":"Value Health"},{"key":"ref21","unstructured":"Enzalutamide for hormone-relapsed non-metastatic prostate cancer. NICE technology appraisal guidance [TA580]; 2019. Available from: https:\/\/www.nice.org.uk\/guidance\/ta580. Accessed February 1, 2021."},{"key":"ref22","unstructured":"Vismodegib for treating basal cell carcinoma. NICE technology appraisal guidance [TA489]; 2017. Available from: https:\/\/www.nice.org.uk\/guidance\/ta489. Accessed February 1, 2021."},{"key":"ref23","unstructured":"Justification to the resolution of the Federal Joint Committee (G-BA) on an amendment of the pharmaceuticals directive (AM-RL): Annex XII \u2013 resolutions on the benefit assessment of medicinal products with new active ingredients according to section 35a SGB V \u2013 palbociclib; 2017. Available from: https:\/\/www.g-ba.de\/downloads\/40-1465-4388\/2017-05-18_AM-RL-XII_Palbociclib_D-264_TrG_EN.pdf. Accessed February 1, 2021."},{"key":"ref24","unstructured":"Justification to the resolution of the Federal Joint Committee (G-BA) on an amendment of the pharmaceuticals directive (AM-RL): Annex XII \u2013 resolutions on the benefit assessment of medicinal products with new active ingredients according to section 35a SGB V abemaciclib (breast cancer; in combination with fulvestrant); 2019. Available from: https:\/\/www.g-ba.de\/downloads\/40-1465-5714\/2019-05-02_AM-RL-XII_Abemaciclib_D-401_TrG_EN.pdf. Accessed February 1, 2021."},{"key":"ref25","unstructured":"Informe de Posicionamiento Terap\u00e9utico de ixazomib (Ninlaro\u00ae) en mieloma m\u00faltiple. [Therapeutic Positioning Report of ixazomib (Ninlaro\u00ae) in multiple myeloma]; 2018. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-ixazomib-Ninlaro-mieloma-multiple.pdf?x54046. Accessed February 1, 2021."},{"key":"ref26","unstructured":"Informe de Posicionamiento Terap\u00e9utico de pembrolizumab (Keytruda\u00ae) en el tratamiento de Linfoma de Hodgkin. [Report on Therapeutic Positioning of pembrolizumab (Keytruda\u00ae) in the treatment of Hodgkin's Lymphoma]; 2018. Available from: Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-pembrolizumab-Keytruda-linfoma-Hodgkin.pdf?x98091. Accessed February 1, 2021."},{"key":"ref27","unstructured":"Nutzenbewertungsverfahren zum Wirkstoff Bosutinib. [Benefit assessment procedure for the active ingredient bosutinib]; 2013. Available from: https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/68\/. Accessed January 12, 2021."},{"key":"ref28","unstructured":"Re-submission bosutinib; 2015. Available from: https:\/\/www.scottishmedicines.org.uk\/media\/1353\/bosutinib__bosulif__resubmission_final_jan_2015_for_website.pdf. Accessed January 12, 2021."},{"key":"ref29","unstructured":"EUnetHTA. Guideline: endpoints used for relative effectiveness assessment: clinical endpoints; 2015. Available from: https:\/\/eunethta.eu\/wp-content\/uploads\/2018\/02\/WP7-SG3-GL-clin_endpoints_amend2015.pdf. Accessed January 23, 2020."},{"key":"ref30","unstructured":"Institute for Clinical and Economic Review. ICER evidence rating matrix: a user\u2019s guide; 2020. Available from: https:\/\/icer.org\/evidence-rating-matrix\/. Accessed January 6, 2020."},{"key":"ref31","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. General methods (version 5.0); 2017. Available from: https:\/\/www.iqwig.de\/download\/General-Methods_Version-5-0.pdf. Accessed January 23, 2020."},{"key":"ref32","unstructured":"NICE Decision Support Unit. A review of studies examining the relationship between progression-free survival and overall survival in advanced or metastatic cancer; 2012. Available from: http:\/\/nicedsu.org.uk\/methods-development\/pfs-os\/. Accessed January 23, 2020."},{"key":"ref33","unstructured":"NICE Decision Support Unit. NICE DSU technical support document 20: multivariate meta-analysis of summary data for combining treatment effects on correlated outcomes and evaluating surrogate endpoints; 2019. Available from: http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2020\/10\/TSD-20-mvmeta-final.pdf. Accessed January 11, 2021."},{"key":"ref34","unstructured":"Pharmaceutical Benefits Advisory Committee Appendix 5. Translating comparative treatment effects of proposed surrogate measures to target clinical outcomes; 2016. Available from: https:\/\/pbac.pbs.gov.au\/appendixes\/appendix-5.html. Accessed January 20, 2020."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","volume":"34","author":"Schnipper","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"key":"ref38","unstructured":"NICE. Methods, processes and topic selection for health technology evaluation: proposals for change; 2021. Available from: https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/chte-methods-and-processes-consultation. Accessed 14 September, 2021."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/13571516.2011.584428","volume":"18","author":"Cook","year":"2011","journal-title":"Int J Econ Bus"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jval.2020.12.018","volume":"24","author":"Fornaro","year":"2021","journal-title":"Value Health"},{"key":"ref41","unstructured":"FDA in brief: FDA oncologic drugs advisory committee to review status of six indications granted accelerated approval; 2021. Available from: https:\/\/www.fda.gov\/news-events\/fda-brief\/fda-brief-fda-oncologic-drugs-advisory-committee-review-status-six-indications-granted-accelerated#:~:text=Since%20the%20inception%20of%20the,oncology%20indications%20have%20been%20withdrawn. Accessed June 15, 2021."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1056\/NEJMp2104846","volume":"384","author":"Beaver","year":"2021","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamainternmed.2016.7761","volume":"177","author":"Rupp","year":"2017","journal-title":"JAMA Intern Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ygyno.2020.01.026","volume":"156","author":"Havrilesky","year":"2020","journal-title":"Gynecol Oncol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","volume":"47","author":"DiMasi","year":"2016","journal-title":"J Health Econ"},{"key":"ref46","unstructured":"Council Directive 89\/105\/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems. Available from: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A31989L0105. Accessed March 16, 2021."},{"key":"ref47","volume-title":"Clinical Measurements in Drug Evaluation","year":"1995"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"e1002447","DOI":"10.1371\/journal.pmed.1002447","volume":"14","author":"Kirkham","year":"2017","journal-title":"PLoS Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"l5221","DOI":"10.1136\/bmj.l5221","volume":"366","author":"Naci","year":"2019","journal-title":"BMJ"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamainternmed.2020.2250","volume":"180","author":"Hilal","year":"2020","journal-title":"JAMA Intern Med"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.1097\/HS9.0000000000000287","volume":"3","author":"F\u00fcrstenau","year":"2019","journal-title":"HemaSphere"},{"key":"ref52","unstructured":"EMA. Guideline on the use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies; 2014. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-use-minimal-residue-disease-endpoint-chronic-lymphocytic-leukaemia-studies_en.pdf. Accessed November 11, 2020."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/S0959-8049(96)00324-3","volume":"33","author":"Burris","year":"1997","journal-title":"Eur J Cancer"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1200\/JCO.2008.19.5339","volume":"27","author":"Korn","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref55","unstructured":"AstraZeneca Press Release. Tagrisso Phase III ADAURA trial will be unblinded early after overwhelming efficacy in the adjuvant treatment of patients with EGFR-mutated lung cancer; 2020. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/tagrisso-phase-iii-adaura-trial-will-be-unblinded-early-after-overwhelming-efficacy-in-The-adjuvant-treatment-of-patients-with-egfr-mutated-lung-cancer.html. Accessed January 11, 2020."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40273-014-0145-y","volume":"32","author":"Ishak","year":"2014","journal-title":"PharmacoEconomics"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1177\/0962280216642264","volume":"27","author":"Latimer","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.1158\/1078-0432.CCR-12-1803","volume":"18","author":"de Claro","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/annonc\/mdv131","volume":"26","author":"Capocaccia","year":"2015","journal-title":"Ann Oncol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/sim.4780120904","volume":"12","author":"Lin","year":"1993","journal-title":"Stat Med"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/QCO.0b013e32835ba6b1","volume":"26","author":"Nakagawa","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12916-016-0640-4","volume":"14","author":"Lazarus","year":"2016","journal-title":"BMC Med"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11908-011-0231-7","volume":"14","author":"Hullsiek","year":"2012","journal-title":"Curr Infect Dis Rep"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40273-014-0219-x","volume":"33","author":"Wilson","year":"2015","journal-title":"PharmacoEconomics"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jclinepi.2021.03.018","volume":"137","author":"Buyse","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.breast.2017.08.008","volume":"37","author":"Muller","year":"2018","journal-title":"Breast"},{"key":"ref68","unstructured":"NICE. Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer -technology appraisal guidance [TA424]: final appraisal document; 2016. Available from: https:\/\/www.nice.org.uk\/guidance\/ta424\/documents\/final-appraisal-determination-document. Accessed March 4, 2021."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2021.01.006","volume":"147","author":"Harbeck","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"e200643","DOI":"10.1001\/jamanetworkopen.2020.0643","volume":"3","author":"Marschner","year":"2020","journal-title":"JAMA Netw Open"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S1470-2045(16)30510-1","volume":"17","author":"Bottomley","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.3802\/jgo.2018.29.e81","volume":"29","author":"Wilson","year":"2018","journal-title":"J Gynecol Oncol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejca.2017.03.019","volume":"78","author":"Joly","year":"2017","journal-title":"Eur J Cancer"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jval.2018.09.2842","volume":"22","author":"Gnanasakthy","year":"2019","journal-title":"Value Health"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s11136-019-02152-6","volume":"28","author":"Wood","year":"2019","journal-title":"Qual Life Res"},{"key":"ref77","unstructured":"Friends of Cancer Research. Broadening the definition of tolerability in cancer clinical trials to better measure the patient experience; 2018. Available from: https:\/\/www.focr.org\/sites\/default\/files\/Comparative%20Tolerability%20Whitepaper_FINAL.pdf. Accessed January 12, 2021."},{"key":"ref78","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1002\/cncr.28940","volume":"120","author":"Havrilesky","year":"2014","journal-title":"Cancer"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"100332","DOI":"10.1016\/j.eclinm.2020.100332","volume":"21","author":"Gyawali","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref80","unstructured":"National Cancer Institute. National Cancer Institute dictionary of cancer terms. Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms. Accessed May 14, 2020."},{"key":"ref81","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40273-020-00935-1","volume":"38","author":"Grigore","year":"2020","journal-title":"PharmacoEconomics"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jval.2016.11.005","volume":"20","author":"Powers","year":"2017","journal-title":"Value Health"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jval.2016.10.011","volume":"20","author":"Ciani","year":"2017","journal-title":"Value Health"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nrclinonc.2010.43","volume":"7","author":"Buyse","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/sim.4780080407","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0272989X21994553","volume":"41","author":"Ciani","year":"2021","journal-title":"Med Decis Making"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s40273-019-00806-4","volume":"37","author":"Ouwens","year":"2019","journal-title":"PharmacoEconomics"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/13696998.2018.1547303","volume":"22","author":"Bullement","year":"2019","journal-title":"J Med Econ"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jval.2020.10.016","volume":"24","author":"Tai","year":"2021","journal-title":"Value Health"},{"key":"ref91","unstructured":"NICE. Broader types of data to be used in development of NICE guidance; 2020. Available from: https:\/\/www.nice.org.uk\/news\/article\/broader-types-of-data-to-be-used-in-development-of-nice-guidance. Accessed November 11, 2020."},{"key":"ref92","unstructured":"NICE Decision Support Unit. The use of real world data for the estimation of treatment effects in NICE decision making; 2016. Available from: http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2018\/05\/RWD-DSU-REPORT-Updated-DECEMBER-2016.pdf. Accessed November 11, 2020."},{"key":"ref93","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.jval.2017.04.003","volume":"20","author":"Lakdawalla","year":"2017","journal-title":"Value Health"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/cancers11010010","volume":"11","author":"Lux","year":"2018","journal-title":"Cancers (Basel)"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.breast.2020.08.011","volume":"54","author":"Schneeweiss","year":"2020","journal-title":"Breast"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13023-020-01370-3","volume":"15","author":"Annemans","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"ref97","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS19-P1-19-02","volume":"80","author":"DeMichele","year":"2020","journal-title":"Cancer Res"}],"container-title":["Cancer Management and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=75706","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=75706","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T20:51:08Z","timestamp":1673729468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/the-impasse-on-overall-survival-in-oncology-reimbursement-decision-mak-peer-reviewed-fulltext-article-CMAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":97,"URL":"https:\/\/doi.org\/10.2147\/cmar.s328058","relation":{},"ISSN":["1179-1322"],"issn-type":[{"value":"1179-1322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}